Gabapentin Capsule
Product Images NDC 71335-1454

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-1454). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 01)

A table titled 'Gabapentin Dosage Based on Renal Function' showing dose regimens related to creatinine clearance levels (mL/min). It details total daily dose ranges in mg/day and specific dose regimens in mg for different dosing frequencies (TID, BID, QD). The table includes supplemental post-hemodialysis doses and footnotes explaining dose adjustments and creatinine clearance estimation.*

FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 03)

A data table titled 'TABLE 2 Risk by Indication for Antiepileptic Drugs in the Pooled Analysis' presenting comparative event rates per 1,000 patients for placebo and drug groups across indications: Epilepsy, Psychiatric, Other, and Total. It includes columns for Placebo Patients with Events, Drug Patients with Events, Relative Risk, and Risk Difference, detailing risks associated with antiepileptic drug use.*

FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 04)

A data table titled 'TABLE 3. Adverse Reactions in Pooled Placebo-Controlled Trials in Postherpetic Neuralgia.' The table compares adverse reaction percentages between Gabapentin (N=336) and placebo (N=227) groups, categorized by body system such as Body as a Whole, Digestive System, Metabolic and Nutritional Disorders, Nervous System, Respiratory System, and Special Senses. It lists specific adverse reactions and their occurrence rates in both groups.*

FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 05)

Table presenting adverse reactions in pooled placebo-controlled add-on trials of gabapentin versus placebo in epilepsy patients over 12 years of age. It lists the percentage of patients experiencing various side effects by system, comparing gabapentin (N=543) to placebo (N=378), including fatigue, somnolence, dizziness, and others.*

FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 06)

Table presenting adverse reactions in a placebo-controlled add-on trial in pediatric epilepsy patients aged 3 to 12 years, comparing incidences of various adverse reactions between gabapentin (N=119) and placebo (N=128) groups across body systems including body as a whole, digestive system, nervous system, and respiratory system.*

FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 07)

Chemical structure diagram of gabapentin, showing its molecular arrangement with a cyclohexane ring and side chains including an amino group and a carboxyl group.*

FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 08)

Table titled 'Controlled PHN Studies: Duration, Dosages, and Number of Patients' presenting data for two studies. It lists study duration, gabapentin target dose in mg/day, and number of patients receiving gabapentin or placebo. Study 1 lasted 8 weeks with a target dose of 3,600 mg/day in 113 patients receiving gabapentin and 116 receiving placebo. Study 2 lasted 7 weeks with target doses of 1,800 and 2,400 mg/day with 223 patients receiving gabapentin and 111 receiving placebo. Total patients are 336 for gabapentin and 227 for placebo. The gabapentin dose is given in 3 divided doses (TID).*

FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 09)

A line graph depicting mean pain score over an 8-week period comparing placebo and Gabapentin 3600 mg/day. The graph is divided into a 4-week dose titration period and a 4-week fixed dose period, showing a decreasing trend of pain scores for Gabapentin relative to placebo across weeks.*

FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 10)

Line graph depicting mean pain scores over a 7-week period, comparing placebo with Gabapentin at 1800 mg/day and 2400 mg/day dosages. The x-axis represents weeks from baseline to week 7, with a 3-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain scores ranging from 0 to 10.*

FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 11)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and gabapentin (GBP) at different dosages. Study 1 shows 12% responder rate for placebo and 29% for GBP 3600 mg. Study 2 shows 14% for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance is indicated with p-values (<0.01 and <0.001).*

FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 12)

A scatter plot comparing percentage differences across daily doses of Gabapentin (600 mg, 900 mg, 1200 mg, 1800 mg) in three studies labeled Study a, Study b, and Study c. The y-axis shows difference percentage, while the x-axis depicts daily dose in milligrams. Different shaped markers correspond to each study with varying trend patterns.*

FDA Label Image

Label Image (Lbl713351454)

Label for Gabapentin 300 mg (CV) oral capsules by Bryant Ranch Prepack, comparing to Neurontin 300 mg capsules from InvaGen Pharmaceuticals. The label includes storage instructions (20°-25°C or 68°-77°F), a dizziness warning, and advises to keep out of reach of children. The package count is 90 capsules, with NDC 71335-1454-1.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.